MACF1 and astrocytoma (excluding glioblastoma): Of some concern, MACF1 (microtubule actin cross-linking factor 1) was found to be predominately elevated in grade III-IV astrocytomas and grade IV glioblastoma, however when treated with TMZ, MACF1 is reduced and diminishes GBM cell proliferative capacity [42].